Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PKLR | P30613 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | USP7 | Q93009 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL238045 | 0.89 | OPRD1 (0.43) | CHRM4OPRK1OPRD1 | |
| SCHEMBL236942 | 0.88 | SMYD2 (0.39) | SMYD2HTTCYP3A4SMN1; SMN2ALDH1A1 | |
| SCHEMBL240139 | 0.77 | TACR1 (0.43) | CHRM4OPRK1OPRD1 | |
| SCHEMBL25329727 | 0.74 | SMYD2 (0.45) | SMYD2HTTCYP3A4SMN1; SMN2CHRM4 | |
| SCHEMBL1845926 | 0.73 | SMYD2 (0.42) | SMYD2HTTCYP3A4SMN1; SMN2ALDH1A1 | |
| SCHEMBL30405175 | 0.73 | SMYD2 (0.39) | SMYD2HTTCYP3A4SMN1; SMN2GAA | |
| SCHEMBL2907725 | 0.72 | SMYD2 (0.37) | SMYD2HTTCYP3A4SMN1; SMN2OPRM1 | |
| SCHEMBL5662573 | 0.71 | ABL1 (0.38) | SMYD2HTTCYP3A4SMN1; SMN2ALDH1A1 | |
| SCHEMBL1291772 | 0.70 | LMNA (0.42) | SMYD2HTTCYP3A4SMN1; SMN2ALDH1A1 | |
| SCHEMBL31216597 | 0.70 | SMYD2 (0.39) | SMYD2HTTCYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | SANOFI-AVENTIS (FR) | 2012-01-05 | — | — | US | disclosed |
| EP-1633735-B1 | DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES, PREPARATION METHODS THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI SA (FR) | 2011-11-30 | — | — | EP | disclosed |
| US-8034818-B2 | Therapeutic uses of derivatives of piperidinyl- and piperazinyl-alkyl carbamates | SANOFI-AVENTIS (FR) | 2011-10-11 | — | — | US | disclosed |
| US-20070142350-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES | SANOFI-AVENTIS (FR) | 2007-06-21 | — | — | US | disclosed |
| US-7214798-B2 | Derivatives of piperidinyl-and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2007-05-08 | — | — | US | disclosed |
| US-20060089344-A1 | Derivatives of piperidinyl-and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2006-04-27 | — | — | US | disclosed |
| EP-1633735-A1 | DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES, PREPARATION METHODS THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004099176-A1 | DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES, PREPARATION METHODS THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089344-A1 | Derivatives of piperidinyl-and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | CLCN2, CNR2, RCC2 | SMYD2 1432/4885HTT 3204/4885CYP3A4 3278/4885 |
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SMYD2 1993/4885HTT 2051/4885CYP3A4 4089/4885 |
| US-20070142350-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3, H1-2 | SMYD2 1897/4885HTT 1734/4885CYP3A4 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.